BTIG Research Has Lowered Expectations for Natera (NASDAQ:NTRA) Stock Price

by · The Cerbat Gem

Natera (NASDAQ:NTRA – Get Free Report) had its price target dropped by analysts at BTIG Research from $260.00 to $250.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. BTIG Research’s target price indicates a potential upside of 25.00% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research note on Monday, January 12th. Evercore reaffirmed an “outperform” rating and issued a $270.00 target price on shares of Natera in a research note on Friday. JPMorgan Chase & Co. boosted their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday. Robert W. Baird set a $265.00 target price on shares of Natera in a research note on Friday. Finally, Morgan Stanley dropped their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $255.33.

View Our Latest Report on NTRA

Natera Trading Up 3.0%

NTRA stock traded up $5.76 during trading on Monday, hitting $200.00. 1,128,215 shares of the stock traded hands, compared to its average volume of 1,277,751. Natera has a one year low of $131.81 and a one year high of $256.36. The stock has a market cap of $28.46 billion, a price-to-earnings ratio of -122.98 and a beta of 1.57. The company has a 50 day simple moving average of $202.23 and a 200 day simple moving average of $215.02.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.05% and a negative return on equity of 15.72%. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period last year, the firm posted ($0.41) EPS. As a group, analysts predict that Natera will post -1.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 902 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $206.16, for a total transaction of $185,956.32. Following the completion of the sale, the chief executive officer directly owned 149,867 shares of the company’s stock, valued at $30,896,580.72. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 38,266 shares of company stock valued at $7,747,808. 5.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth raised its stake in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Natera during the second quarter worth approximately $558,000. 99.90% of the stock is owned by institutional investors.

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Articles